Biogen Inc (BIIB)

HEALTH CARE: PHARMACEUTICALS
SIC: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)

225 BINNEY STREET CAMBRIDGE, MA 02142

At Biogen, mission is clear: company is pioneer in neuroscience. Biogen discovers, develops and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. One of the world's first global biotechnology companies, Biogen was founded in 1978 by Charles Weissmann, Heinz Schaller, Kenneth Murray and Nobel Prize winners Walter Gilbert and Phillip Sharp. Today Biogen has the leading portfolio of medicines to treat multiple sclerosis, has introduced the first approved treatment for spinal muscular atrophy, commercializes biosimilars of advanced biologics and is focused on advancing research programs in multiple sclerosis and neuroimmunology, Alzheimer's disease and dementia, neuromuscular disorders, movement disorders, ophthalmology, neuropsychiatry, immunology, acute neurology and neuropathic pain.

Data as of 2021-05-01 09:54:31 -0400
Market Cap40.248 Billion Shares Outstanding150.555 Million Avg 30-day Volume931.871 Thousand
P/E Ratio13.36381 Dividend Yield0.0 EPS19.29
Price/Sales3.06 Debt to Equity2.3 EBITDA4.916 Billion
Price to Book Value3.84 Forward PE14.65 Enterprise Value45.924 Billion
Total Cash2.61 Billion Current Debt3.742 Billion Gross Profit11.639 Billion
BETA0.0 52-week High/Low363.92 / 223.25 Next Earnings Date Price to Cash FLow (P/CF) 70.9542
Data provided by IEX Cloud
View SEC Filings from BIIB instead.
Q4 2020 All 13F Filers Prior Change Hedge Funds 1 Prior Change
In top 10: 6 17 -64.71% 12 (0.72%) 16 (1.0%) -25.0%
Funds Holding: 1029 1026 0.29% 218 (13.09%) 229 (14.25%) -4.8%
13F shares: 128.608 Million 128.957 Million -0.27% 31.42 Million 32.539 Million -3.44%
% Ownership 83.576 83.8029 -0.27% 20.4182 21.1455 -3.44%
New Positions: 162 96 68.75% 33 22 50.0%
Increased Positions 278 306 -9.15% 71 68 4.41%
Closed Positions 146 91 60.44% 44 26 69.23%
Reduced Positions 425 423 0.47% 89 101 -11.88%
Total Calls 7.504 Million 4.465 Million 68.06% 2.757 Million 1.543 Million 78.7%
Total Puts 6.334 Million 4.975 Million 27.32% 2.014 Million 1.733 Million 16.18%
PUT/CALL Ratio 0.84 1.11 -24.32% 0.73 1.12 -34.82%
1 hedge funds and active managers as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding BIIB (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding BIIB BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

ALEXANDER SUSAN H EVP CHIEF LEGAL OFF & CORP SEC

  • Officer
10,870 2021-02-18 3

SANDROCK ALFRED EVP, RESEARCH & DEVELOPMENT

  • Officer
14,500 2021-02-18 4

VOUNATSOS MICHEL CHIEF EXECUTIVE OFFICER

  • Officer
  • Director
45,310 2021-02-18 4

GREGORY GINGER EVP, HUMAN RESOURCES

  • Officer
10,150 2021-02-18 4

GUINDO CHIRFI EVP GLOB. PROD STRAT AND COMM

  • Officer
14,500 2021-02-18 3

KRAMER ROBIN SVP, CHIEF ACCOUNTING OFFICER

  • Officer
2,900 2021-02-18 4

GALDES ALPHONSE EVP PHARMACEUTICAL OPER & TECH

  • Officer
10,870 2021-02-18 3

MCDONNELL MICHAEL R EVP, CHIEF FINANCIAL OFFICER

  • Officer
14,500 2021-02-18 3

MANTAS JESUS B

  • Director
2,943 2021-02-09 2

POSNER BRIAN S

  • Director
7,760 2020-12-31 2

PANGIA ROBERT W

  • Director
20,632 2020-12-31 2

LEAMING NANCY

  • Director
12,988 2020-06-03 1

SHERWIN STEPHEN A

  • Director
16,328 2020-06-03 1

ROWINSKY ERIC K

  • Director
17,069 2020-06-03 1

DENNER ALEXANDER J

  • Director
655,954 2020-06-03 1

DORSA CAROLINE

  • Director
21,097 2020-06-03 1

PAPADOPOULOS STELIOS

  • Director
34,771 2020-06-03 1

MULLIGAN RICHARD

  • Director
12,954 2020-06-03 1

HAWKINS WILLIAM A

  • Director
2,045 2020-06-03 1

CAPELLO JEFFREY D EVP & CHIEF FINANCIAL OFFICER

  • Officer
3,118 2020-02-12 0

KARP DANIEL EVP, CORPORATE DEVELOPMENT

  • Officer
930 2020-02-12 0

SCHENK LYNN

  • Director
12,132 2019-06-19 0

EHLERS MICHAEL D EVP, RESEARCH AND DEVELOPMENT

  • Officer
8,025 2019-06-01 0

MCKENZIE PAUL EVP PHARMACEUTICAL OPER & TECH

  • Officer
7,235 2019-03-01 0

COVINO GREGORY F VP, CHIEF ACCOUNTING OFFICER

  • Officer
0 2018-03-01 0

KRESS JEAN-PAUL EVP PRES INT'L & GLOBAL HD GTO

  • Officer
0 2017-07-03 0

CLANCY PAUL J EXECUTIVE VP AND CFO

  • Officer
10,813 2017-04-25 0

DIPIETRO KENNETH EVP HUMAN RESOURCES

  • Officer
7,177 2017-02-28 0

KARABOUTIS ADRIANA EVP, TECH, BUS. SOL & CORP AFF

  • Officer
8,752 2017-02-28 0

SCANGOS GEORGE A CHIEF EXECUTIVE OFFICER

  • Officer
  • Director
65,535 2016-07-21 0

KOPPEL ADAM EVP, STRATEGY AND BUS. DEV.

  • Officer
No longer subject to file 2016-06-06 0

ARTAVANIS-TSAKONAS SPYRIDON EVP, CHIEF SCIENTIFIC OFFICER

  • Officer
3,150 2016-04-02 0

COX JOHN EVP PHARMACEUTICAL OPER & TECH

  • Officer
39,045 2016-04-01 0

HOLTZMAN STEVEN H EVP CORPORATE DEVELOPMENT

  • Officer
No longer subject to file 2016-02-23 0

WILLIAMS DOUGLAS E EVP RESEARCH & DEVELOPMENT

  • Officer
11,817 2015-06-19 0

KINGSLEY STUART A EVP, GLOBAL COMM. OPERATIONS

  • Officer
0 2015-02-23 0

YOUNG WILLIAM

  • Director
18,509 2014-01-08 0

PAWLICKI RAYMOND SVP, CHIEF INFORMATION OFFICER

  • Officer
8,710 2013-11-22 0

GAGNON ROBERT E. VICE PRESIDENT, FINANCE

  • Officer
3,999 2012-02-28 0

GRANATA FRANCESCO EVP GLOBAL COMMERCIAL OPERATIO

  • Officer
3,529 2012-02-01 0

SCHNEIER CRAIG ERIC EVP, HR, PUBLIC AFFAIRS & COMM

  • Officer
10,661 2011-03-01 0

MACLEAN MICHAEL F SVP, CHIEF ACCOUNTING OFFICER

  • Officer
10,681 2010-10-01 0

MULLEN JAMES C CEO & PRESIDENT

  • Officer
  • Director
No longer subject to file 2010-06-08 0

ROSS BRUCE

  • Director
No longer subject to file 2010-06-08 0

HAMM ROBERT A CHIEF OPERATING OFFICER

  • Officer
27,212 2010-04-23 0

LYTTON MICHAEL EVP CORPORATE & BUSINESS DEVEL

  • Officer
18,869 2010-03-02 0

PICKETT CECIL B PRESIDENT, R & D

  • Officer
  • Director
No longer subject to file 2009-10-02 0

SHARP PHILIP A

  • Director
470,278 2009-06-03 0

DEKKERS MARIJN E

  • Director
6,595 2009-06-03 0

HASLER HANS PETER CHIEF OPERATING OFFICER

  • Officer
53,261 2009-02-24 0

DUNN JOHN MICHAEL EVP, NEW VENTURES

  • Officer
No longer subject to file 2009-02-24 0

WIGGINS MARK C EVP CORP. AND BUS. DEV.

  • Officer
22,780 2008-09-26 0

HASNAIN FAHEEM EVP, ONCOLOGY/RHEUMATOLOGY SBU

  • Officer
25,454 2008-07-09 0

GLASSBERG ALAN

  • Director
5,600 2008-06-19 0

BEST LAWRENCE C

  • Director
5,600 2008-06-19 0

KELLER THOMAS F

  • Director
1,250 2007-10-15 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
No current insider transactions

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

IBR Securities Loan Availability

Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

Security Date/Time Rebate Rate Fee Rate Shares Available
BIOGEN INC BIIB 2021-05-05 22:15:02 UTC -0.6829 0.7329 5400000
BIOGEN INC BIIB 2021-05-05 21:45:03 UTC -0.6829 0.7329 5400000
BIOGEN INC BIIB 2021-05-05 21:15:03 UTC -0.6829 0.7329 5400000
BIOGEN INC BIIB 2021-05-05 20:45:03 UTC -0.6829 0.7329 5400000
BIOGEN INC BIIB 2021-05-05 20:15:03 UTC -0.6829 0.7329 5400000
BIOGEN INC BIIB 2021-05-05 19:45:02 UTC -0.6829 0.7329 5400000
BIOGEN INC BIIB 2021-05-05 19:15:03 UTC -0.6829 0.7329 5300000
BIOGEN INC BIIB 2021-05-05 18:45:03 UTC -0.2035 0.2535 5300000
BIOGEN INC BIIB 2021-05-05 18:15:03 UTC -0.2035 0.2535 5300000
BIOGEN INC BIIB 2021-05-05 17:45:03 UTC -0.2035 0.2535 5300000
BIOGEN INC BIIB 2021-05-05 17:15:03 UTC -0.2035 0.2535 5300000
BIOGEN INC BIIB 2021-05-05 16:45:03 UTC -0.2046 0.2546 5300000
BIOGEN INC BIIB 2021-05-05 16:15:03 UTC -0.2046 0.2546 5300000
BIOGEN INC BIIB 2021-05-05 15:45:03 UTC -0.2046 0.2546 5300000
BIOGEN INC BIIB 2021-05-05 15:15:02 UTC -0.2046 0.2546 5300000
BIOGEN INC BIIB 2021-05-05 14:45:04 UTC -0.2 0.25 5300000
BIOGEN INC BIIB 2021-05-05 14:15:03 UTC -0.2 0.25 5300000
BIOGEN INC BIIB 2021-05-05 13:45:03 UTC -0.2 0.25 5300000
BIOGEN INC BIIB 2021-05-05 13:15:03 UTC -0.2 0.25 5300000
BIOGEN INC BIIB 2021-05-05 12:45:02 UTC -0.2 0.25 5300000

Current Active Short Positions

Holder Issuer Net Short Position Position Date Origin
AGF Investments Trust- AGFIQ U.S. Market Neutral Momentum Fund BIIB -96.0 shares, $-23506.56 2020-12-31 N-PORT
AdvisorShares Trust- AdvisorShares Dorsey Wright Short ETF BIIB -1541.0 shares, $-377329.26 2020-12-31 N-PORT
Blackstone Alternative Investment Funds- Blackstone Alternative Multi-Strategy Fund BIIB -13900.0 shares, $-3403554.0 2020-12-31 N-PORT
VANGUARD TRUSTEES' EQUITY FUND- VANGUARD ALTERNATIVE STRATEGIES FUND BIIB -678.0 shares, $-191609.58 2021-01-31 N-PORT
Principal Funds, Inc- Global Multi-Strategy Fund BIIB 705.0 shares, $-192380.4 2021-02-28 N-PORT

Elevate your investments